The Kevin Trudeau Show: 6-30-10
Today, Kevin Trudeau and Erich ‘Mancow’ Muller take over the airwaves to uncover government lies and the truth behind the man in your dreams!
Self Help:
Organic Dairy Products Contribute to Weight Loss
Vitamin D Deficiency Leads to High Blood Pressure
Health:
Drug Makers Rake in Billions Battling H1N1 Flu
Blood Thinner Drug Causes Death
Vaccine for Cocaine Addiction
NWO:
White House Admits They Control the Media
Everything Kevin:
Become An Insider!
Support Kevin!
Kevin is on YouTube!
Sign Up For Kevin’s FREE Podcast
Follow Kevin on Twitter
Become Kevin’s Friend on Facebook
Kevin’s Film Club
Kevin’s Book Club
Take Trudeau on the Go! Click here to download this show to your iPod, mp3 player, or PC through iTunes!
Click BELOW to watch the Kevin Trudeau Show LIVE!
Prescription Blood Thinners Interfere with Heartburn Drugs
January 12, 2010 by admin
Filed under News Stories
January12, 2010
NaturalNews
by E. Huff
The U.S. Food and Drug Administration (FDA) has issued a warning about popular over-the-counter heartburn drugs like Prilosec and Prevacid. When taken in combination with blood-thinning drugs like Plavix, the interaction can diminish the effectiveness of the blood thinner medications by more than half.
Because taking Plavix often causes an upset stomach, it is typically prescribed along with drugs that block stomach acid. Proton pump inhibitor drugs like Nexium and Prilosec that perform the task also block the enzyme needed by the body to break down and process Plavix.
Sanofi-Aventis and Bristol-Myers Squibb, the marketers of Plavix, have begun including warnings on the product labels about the interaction side effects. The FDA is recommending that people who take Plavix switch to stomach acid blocking drugs in the H-2 blocker family which it claims do not have any known interactions with blood-thinning drugs.
Not only do the drugs interact with one another to diminish potency but they put patients’ health at further risk. Last year, it was discovered in a research study that taking Plavix doubles a person’s chance of suffering from a heart attack or stroke This is an ironic find when considering the fact that Plavix is commonly prescribed as a preventive drug against strokes and heart attacks.
Plavix has also been found to cause a rare but serious blood-related disease called thrombotic thrombocytopenic purpura (TTP). If left untreated, TTP has a 95 percent fatality rate and Plavix is one of only a few drugs known to cause this odd disease.
The risk of developing severe gastrointestinal bleeding and ulcers from using Plavix is twelve times higher than in those who take low-dose aspirin instead. Even though aspirin has its own dangers, it is far safer than Plavix and has been shown to be more effective.
Global sales of Plavix top $9 billion, making it the second best-selling drug in the world next to Pfizer’s cholesterol drug, Lipitor. Since it is a blockbuster drug that rakes in high profits, it is highly unlikely that it will ever be removed from the market despite the fact that it is ineffective and dangerous.
Nattokinase, an enzyme taken from the vegetable cheese Natto, is a natural alternative to Plavix that works effectively at dissolving blood clots and preventing the accumulation of red blood cells. It also does not increase bleeding time like Plavix does. Serrapeptase is another similar enzyme that performs a similar function and is far preferable to any pharmaceutical drug.
Drug Ads Costing Us Money in Heathcare
November 25, 2009 by admin
Filed under News Stories
Novemeber 25, 2009
Reuters
When consumer advertising began for the popular blood-thinner Plavix, Medicaid insurance programs for the poor and disabled spent millions more on the drug, even though the ads did not tempt doctors to write more prescriptions, researchers reported on Monday.
They said the study suggested that while ads might not directly increase the number of prescriptions, they still affect the cost of publicly funded healthcare because drugmakers appear to build the cost of the ads into their prices.
“Consequently, payers and policymakers should appropriately still be concerned about direct-to-consumer advertising for publicly funded reimbursement programs such as Medicare and Medicaid,” Michael Law of the Centre for Health Services and Policy Research at the University of British Columbia, and colleagues wrote in the Archives of Internal Medicine.
The team studied pharmacy data on Plavix or clopidogrel, the $9 billion-a-year seller made by Sanofi-Aventis (SASY.PA) and Bristol-Myers Squibb (BMY.N). They looked at 27 Medicaid programs from 1999 through 2005.
Plavix is used widely to treat heart attack patients. It works in a similar way to aspirin by stopping platelets — tiny blood cells vital for the normal clotting process — from clumping together.
From 1999 to 2000, there were no consumer-directed ads for Plavix. But from 2001 to 2005, U.S. advertising spending for Plavix topped $350 million, or an average of $70 million a year.
During the study period, doctors servicing Medicaid patients did not change the prescribing trends, but the amount of money spent by Medicaid on the drug rose dramatically.
The Kevin Trudeau Show: 10-21-09
Today, Kevin Trudeau and Erich ‘Mancow’ Muller take over the airwaves to uncover government lies and the truth behind the man in your dreams!
Plus, get the headlines you aren’t hearing anywhere else:
White House Admits They Control the Media
Drug Makers Rake in Billions Battling H1N1 Flu
Blood Thinner Drug Causes Death
Organic Dairy Products Contribute to Weight Loss
Vitamin D Deficiency Leads to High Blood Pressure
Take Trudeau on the Go! Click here to download this show to your iPod, mp3 player, or PC through iTunes!
Click below to hear The Kevin Trudeau Show RIGHT NOW!!!
Blood Thinner Effient Gets FDA Approval with Warning
July 13, 2009 by admin
Filed under News Stories
The approval makes Lilly’s Effient the first real competition to the blood thinner Plavix, the world’s second-best selling medication made by Sanofi-Aventis and Bristol-Myers Squibb.
The FDA delayed its decision on Effient multiple times during an 18-month review, as agency staffers weighed the drug’s benefits versus its risks.
A study of over 13,000 patients conducted by Lilly found that Effient prevents more heart attacks than Plavix, but also causes more internal bleeding.
The FDA said Effient will carry a boxed warning to alert physicians to the risks of “significant, sometimes fatal, bleeding.” The boxed warning is reserved for issues that can cause serious injury or death.
The drug should not be taken by patients with a history of bleeding, stroke or who are undergoing surgery, the FDA said.
“Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug,” said Dr. John Jenkins, FDA’s director of new drugs.
The drug offers an alternative treatment for preventing dangerous blood clots that can lead to heart attack or stroke, Jenkins said. Company studies showed 7% of patients taking Effient experienced nonfatal heart attacks, compared with 9.1% of patients taking Plavix. Despite lower rates of certain heart attacks, the actual rates of death were similar for both drugs.
Indianapolis-based Lilly developed Effient, known chemically as prasugrel, with Japanese drugmaker Daiichi Sankyo Co. The two companies will share revenue.
“After more than a decade of research and testing, we are proud to provide this new treatment option to patients with acute coronary syndrome,” Daiichi President Takashi Shoda said in a statement.
Wall Street analysts say Effient sales could reach an estimated $1 billion annually, compared with the $4.9 billion racked up by Plavix last year.
Like Plavix, Effient prevents blood platelets from sticking together and forming potentially dangerous clots. But where Plavix is approved for use in a wide range of patients, Effient is only approved for those undergoing angioplasty, a common procedure in which an inflatable balloon is used to clear arteries clogged with plaque.
Approval of Effient was considered crucial for Lilly because patents protecting its four best-selling drugs expire by 2013.
But even if the drug reaches the $1 billion mark, it will have trouble replacing the revenue of Lilly’s best-selling product, the anti-psychotic Zyprexa, which garnered $4.7 billion in sales last year.
